A prospective observational study investigating clinicopathological and molecular biological features in FGFR2-fusion positive biliary tract cancer
Not Applicable
- Conditions
- bilary tract cancer
- Registration Number
- JPRN-UMIN000014767
- Lead Sponsor
- Exploratory Oncology Research & Clinical Trial Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of FGFR-fusion gene positive patients in intrahepatic biliary tract cancer
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FGFR2-fusion driven biliary tract cancer progression in the JPRN-UMIN000014767 study?
How effective are FGFR inhibitors compared to standard chemotherapy in FGFR2-fusion positive biliary tract cancer patients?
Which biomarkers correlate with prognosis in FGFR2-fusion positive biliary tract cancer as observed in JPRN-UMIN000014767?
What adverse events are associated with FGFR2-targeted therapies in biliary tract cancer and how are they managed?
Are there combination therapies involving FGFR inhibitors showing promise in FGFR2-fusion positive biliary tract cancer trials?